Expansion Leverages Daxor’s ezBVA Lab to Deliver 98% Accurate Diagnostics with Zero Capital Investment  Oak Ridge, TN, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, continues its strategic expansion into the outpatient cardiology market with the opening of a new BVA program at a leading healthcare facility in Southern Middle Tennessee. This integration brings Daxor’s state-of-the-art testing to a high-volume preventative care set ...

Core Viewpoint - Daxor Corporation has entered into a definitive agreement for the purchase and sale of 765,958 shares of its common stock at a price of $11.75 per share, with expected gross proceeds of approximately $9 million [1][2]. Group 1: Offering Details - The offering is expected to close on or about January 26, 2026, subject to customary closing conditions [1]. - Lake Street Capital Markets, LLC is acting as the exclusive placement agent for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate purposes, including working capital [2]. Group 3: Company Overview - Daxor Corporation addresses a significant issue in healthcare related to the inability to accurately measure blood volume, which can lead to suboptimal patient care and increased hospital stays [5]. - The company manufactures and distributes a patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic system that provides real-time, precise data to improve patient outcomes [5]. - Daxor operates a state-of-the-art manufacturing facility in the U.S. and is positioned for accelerated market expansion [5].

Core Insights - Daxor Corporation is expanding its Blood Volume Analysis (BVA) platform into three new facilities, indicating accelerating market adoption and its role in precision fluid management [1][2] - The company's dual-solution strategy, which includes the on-site BVA analyzer and the CLIA-certified ezBVA Lab Service, is driving strong sales momentum as clinicians increasingly adopt this diagnostic tool [2][3] Company Overview - Daxor Corporation addresses the healthcare challenge of accurately measuring blood volume, which can lead to suboptimal care and increased costs for conditions like heart failure [3] - With 50 years of experience, Daxor manufactures and distributes its FDA-cleared BVA diagnostic, providing real-time, precise data to empower clinicians in making individualized treatment decisions [3] Recent Developments - The ezBVA Lab has been adopted by various healthcare facilities, including the Upper Midwest Integrated Health System for cardiology diagnostics and an Ohio Academic Medical Center for heart failure management [6] - The Southwest Cardiology Group Practice has onboarded the new BVA Analyzer for immediate in-office volume assessment, showcasing the tool's versatility across different healthcare settings [6]

Core Insights - Daxor Corporation is participating in the Maxim Growth Summit, a premier small-cap investor event featuring 40 promising healthcare companies [1][7] - The event will take place on October 22-23, 2025, at the Hard Rock Hotel in New York City, with Daxor's CEO Michael Feldschuh engaging with institutional investors [1][2] Company Overview - Daxor Corporation focuses on addressing the healthcare industry's challenge of accurately measuring blood volume, which is crucial for optimal patient care and reducing hospital stays [4] - The company has developed a patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic system that provides real-time, precise data, enabling clinicians to make better treatment decisions [4] - Daxor operates a state-of-the-art 20,000-square-foot manufacturing facility in the U.S. and is ISO certified, positioning it for market expansion [4]

Core Insights - Daxor Corporation will showcase its next-generation Blood Volume Analysis (BVA) diagnostic system at the MedAxiom Cardiovascular Transforum Fall'25 Conference, which is a key event for cardiovascular organizational performance solutions [1][2] - The launch of the new BVA system is expected to enhance sales momentum and strengthen market leadership by addressing critical issues such as hospital readmissions and resource optimization [2] - Daxor is focused on solving the healthcare challenge of accurately measuring blood volume, which is crucial for improving patient care and reducing hospital stays, particularly for conditions like heart failure [3] Company Overview - Daxor Corporation is recognized as a leader in blood volume measurement technology, with a patented, FDA-cleared BVA diagnostic system that provides real-time, precise data [3] - The company has 50 years of experience in the industry and operates a state-of-the-art manufacturing facility in the U.S., which supports its market expansion efforts [3] - Daxor's technology aims to empower clinicians to make individualized treatment decisions, thereby improving patient outcomes and enhancing efficiencies in value-based healthcare [3]

Core Insights - Daxor Corporation's BVA technology significantly reduces hospital readmissions and improves survival rates in high-cost heart failure segments, validated by new clinical data presented at the HFSA Annual Scientific Meeting [1][3] - The newly FDA-cleared BVA analyzer is expected to capture a substantial share of the multi-billion-dollar market due to its enhanced ease of use, speed, and over 95% accuracy [2][3] Clinical Validation - Clinical findings indicate that patients optimally managed with BVA technology experienced zero unplanned readmissions, contrasting sharply with 57-77% for those with imbalances in blood volume [7] - The use of BVA-guided care in LVAD implantation resulted in improved outcomes, increasing 30-day survival from 90.3% to 93.6% and 1-year survival from 79.6% to 87.8%, while reducing 30-day readmissions from 28.6% to 18.5% [7] - Patients with Cardiac Amyloidosis showed significantly higher total blood and plasma volumes, indicating the diagnostic potential of BVA for accurate treatment [7] Company Overview - Daxor Corporation addresses the critical issue of accurately measuring blood volume, which is essential for optimal care in high-cost medical conditions like heart failure [4] - The company has 50 years of experience and operates a state-of-the-art manufacturing facility, positioning it for accelerated market expansion [4]

Core Insights - Daxor Corporation will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City [1] - The presentation will be available on-demand starting September 5, 2025, at 7:00 a.m. ET [1] Company Overview - Daxor Corporation is addressing a significant issue in healthcare, specifically the inability to accurately measure blood volume, which can lead to suboptimal patient care and increased hospital stays [3] - The company has developed a patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic system that provides real-time, precise data, enabling clinicians to make better treatment decisions [3] - Daxor has 50 years of experience in the field and operates a state-of-the-art 20,000-square-foot manufacturing facility in the U.S., positioning it for market expansion [3] Investor Engagement - Investors interested in the presentation can register for the conference through a provided link [2] - CEO Michael Feldschuh will be available for one-on-one meetings with registered investors at the conference [2] - For further inquiries, investors can contact Bret Shapiro at CORE IR via phone or email [2][6]